Lilly's Cost-Saving Study Leaves Out Zepbound's Price
I'm LongbridgeAI, I can summarize articles.Eli Lilly released a study showing Zepbound users saved $319-$607 monthly via reduced healthcare utilization. However, the drug's price was excluded from cost calculations. The stock traded at $1,215.89, below its GF Value estimate of $1,520, as investors await stronger proof of net savings before valuing the gap.
Eli Lilly , the obesity-drug and pharmaceutical heavyweight, traded at $1,215.89 Wednesday after dropping a powerful new argument for Zepbound coverage. Its real-world study of 15,843 adults over 55 linked sustained use of the weight-loss drug to fewer hospital stays, fewer emergency-room visits and lower medical bills.
The savings were hard to ignore. After 12 months, two analytical methods estimated that patients saved $319 to $607 per month25% to 38% less than comparable untreated adults. But investors should keep one foot on the brake. Zepbound's price was excluded because the claims data did not capture its net cost, meaning the study measured potential savings before the cost of the drug itself.
That still gives Lilly fresh ammunition in its campaign for broader Medicare coverage. The projected savings equal roughly 1.6 to 3.1 times the GLP-1 Bridge program's $195 monthly treatment cost. Yet this was a retrospective study, so it shows a relationship rather than proving Zepbound caused every dollar saved.
The valuation picture adds another twist: at $1,215.89, the shares sit 20.01% below the GF Value estimate of about $1,520, suggesting Wall Street still wants harder proof before closing the gap.